GLP-1 Receptor Agonist Global Market Report 2024

The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to the increasing prevalence of diabetes, the clinical efficacy of treatments, growing patient awareness and acceptance, global health initiatives, and the preference among patients for injectable therapies.

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the increasing emphasis on lifestyle management, the adoption of personalized medicine approaches, the expansion of indications, the development of next-generation products, and integration into combination therapies. Major trends expected in the forecast period include the introduction of oral formulations, a focus on combination therapies, strategic partnerships and collaborations, considerations for reimbursement policies and access, and the adoption of patient-centric approaches.

The growth of the GLP-1 receptor agonist market is anticipated to be fueled by the increasing prevalence of diabetes. Diabetes is a chronic condition resulting from inadequate insulin production by the pancreas or ineffective use of the produced insulin by the body. High blood sugar is a characteristic symptom of this metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists play a crucial role in diabetes management by stimulating the production of insulin, thereby lowering blood sugar levels. The International Diabetes Federation reported in December 2021 that approximately 537 million adults globally are living with diabetes, and this number is expected to rise to 643 million by 2030. Hence, the escalating prevalence of diabetes is a significant factor driving the growth of the GLP-1 receptor agonist market.

The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.

A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.

Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.

In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.

Major companies operating in the glp-1 receptor agonist market report are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., CymaBay Therapeutics Inc., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., Genentech Inc., GlaxoSmithKline plc, HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Kowa Company Ltd., LG Chem Ltd., Ligand Pharmaceuticals Incorporated, Merck & Co. Inc., Novartis AG.

North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.

The GLP-1 receptor agonist market research report is one of a series of new reports that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.